Trials / Completed
CompletedNCT03278379
Avelumab in G2-3 NET
A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Sunnybrook Health Sciences Centre · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol . |
Timeline
- Start date
- 2017-11-15
- Primary completion
- 2021-07-26
- Completion
- 2023-07-06
- First posted
- 2017-09-11
- Last updated
- 2024-12-24
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03278379. Inclusion in this directory is not an endorsement.